Retatrutide Phase 3 Clinical Trial Results: The Benefits Beyond Weight Loss
By RUOcodes.com Research Team
Published: · Updated: Sep 6, 2026
Retatrutide Phase 3 clinical trial results: weight loss outcomes, metabolic benefits beyond GLP-1, and what the data means for researchers in 2026.
Research Use Only. For informational and educational purposes only. Nothing in this article constitutes medical advice. Direct Answer Retatrutide 's phase 3 trials showed average weight loss of 28-30% of body weight — the largest reduction ever documented for a pharmaceutical compound — driven by a triple-receptor mechanism (GLP-1, GIP, and glucagon) that also improved blood sugar, liver fat, lipid profiles, and inflammatory markers, in some cases independent of the weight loss itself. Average weight loss in phase 3 trials: 28-30% of body weight, the largest ever recorded for a pharmaceutical Retatrutide is a triple agonist: GLP-1, GIP, and glucagon receptors simultaneously The TRANSCEND-T2D-1 trial measured HbA1c improvements at a 12 mg weekly dose in adults with type 2 diabetes Retatrutide's Triple Mechanism Receptor Effect GLP-1 Appetite suppression, insulin secretion, gastric emptying modulation GIP Enhanced insulin response, additional fat-loss effect Glucagon Hepatic fat oxidation, increased resting energy expenditure By now, most people following the GLP-1 space have seen the headline number: retatrutide , Eli Lilly's investigational triple agonist, has produced average weight loss of approximately 28 to 30 percent of body weight in phase 3 trials — the largest weight-reduction outcomes ever documented for a pharmaceutical compound. That number is significant enough on its own to command attention. But it is also the wrong place to stop reading. What the phase 3 data actually show is a compound that rewires metabolic function across multiple organ systems simultaneously. The weight loss is real and it is record-setting. The deeper story is what happens to the body's glucose regulation, liver fat, lipid profile, inflammatory burden, joint pain, sleep, and energy expenditure while that weight is coming off — and in some cases independent of the weight loss itself. This post covers that deeper story, section by section, based on phase 3 trial data and clinical s…
← Back to Blog